These include imatinib for bcr-abl chronic myelogenous leukemia (CML) and c-kit positive gastrointestinal stromal tumors (GIST), as well as gefitinib for EGFR mutant tumors [1–3]. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.